ATE382693T1 - Impfstoffe gegen neurotoxine von clostridium botulinum - Google Patents

Impfstoffe gegen neurotoxine von clostridium botulinum

Info

Publication number
ATE382693T1
ATE382693T1 AT99940801T AT99940801T ATE382693T1 AT E382693 T1 ATE382693 T1 AT E382693T1 AT 99940801 T AT99940801 T AT 99940801T AT 99940801 T AT99940801 T AT 99940801T AT E382693 T1 ATE382693 T1 AT E382693T1
Authority
AT
Austria
Prior art keywords
clostridium botulinum
botulinum neurotoxins
vaccines against
against clostridium
neurotoxins
Prior art date
Application number
AT99940801T
Other languages
English (en)
Inventor
John Lee
Peter Pushko
Jonathan Smith
Michael Parker
Mark Dertzbaugh
Leonard Smith
Original Assignee
U S Army Medical Res Inst Of I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Army Medical Res Inst Of I filed Critical U S Army Medical Res Inst Of I
Application granted granted Critical
Publication of ATE382693T1 publication Critical patent/ATE382693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99940801T 1998-07-10 1999-07-09 Impfstoffe gegen neurotoxine von clostridium botulinum ATE382693T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
US13387099P 1999-05-12 1999-05-12

Publications (1)

Publication Number Publication Date
ATE382693T1 true ATE382693T1 (de) 2008-01-15

Family

ID=26785647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940801T ATE382693T1 (de) 1998-07-10 1999-07-09 Impfstoffe gegen neurotoxine von clostridium botulinum

Country Status (7)

Country Link
US (1) US6495143B2 (de)
EP (1) EP1119626B1 (de)
AT (1) ATE382693T1 (de)
AU (1) AU759461B2 (de)
CA (1) CA2336587A1 (de)
DE (1) DE69937890D1 (de)
WO (1) WO2000002524A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2428270C (en) * 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2003012117A1 (en) * 2001-07-28 2003-02-13 The Secretary Of State For Defence Dna vaccine
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
EP1531859A4 (de) * 2002-05-31 2005-12-07 Univ Jefferson Zusammensetzungen und verfahren für den transepithelialen molekültransport
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CA2492160A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
EP1687033A4 (de) * 2003-11-12 2008-06-11 Us Navy Verbesserung der impfstoff-induzierten immunreaktionen und schutz durch heterologe verstärkung mit alphavirus replicon vakzine
CN1989250B (zh) 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
EP2153848A3 (de) * 2005-01-27 2010-07-21 The Regents of the University of California Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
WO2009023549A2 (en) * 2007-08-09 2009-02-19 University Of Rochester Vaccine against botulism
US8445650B2 (en) 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
AU2014240116B2 (en) * 2013-03-15 2016-12-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
WO1998008540A1 (en) * 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for clostridium botulinum neurotoxin
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins

Also Published As

Publication number Publication date
WO2000002524A2 (en) 2000-01-20
WO2000002524A3 (en) 2001-05-31
US20020034521A1 (en) 2002-03-21
WO2000002524A9 (en) 2000-07-13
EP1119626B1 (de) 2008-01-02
US6495143B2 (en) 2002-12-17
DE69937890D1 (de) 2008-02-14
CA2336587A1 (en) 2000-01-20
AU5458399A (en) 2000-02-01
EP1119626A2 (de) 2001-08-01
AU759461B2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
DE69937890D1 (de) Impfstoffe gegen neurotoxine von clostridium botulinum
CY1109531T1 (el) Πρωτεϊνες συντηξης του μυκοβακτηριδιου της φυματιωσης
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
DK1163008T3 (da) Anvendelse af trehalose til stabilisering af en flydende vaccine
ATE236622T1 (de) Blockcopolymere
DE69941454D1 (de) Impfstoff gegen staphylokokken-vergiftung
PT1280541E (pt) Utilizacao de estirpes acetogenicas hidrogenotroficas para a prevencao ou o tratamento de disturbios digestivos
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
BRPI0412265A (pt) uso de calcitonina em osteoartrite
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
NO20031860L (no) Kahalalid F
DK0946730T3 (da) Mutanter af streptokok-toksin C og fremgangsmåder til anvendelse
WO2001051523A3 (en) Anti-angiogenic proteins and fragments and methods of use thereof
FR2771751B1 (fr) Erythrovirus et ses applications
DE69737032D1 (de) Mutanten von streptococcaltoxinen und vefahren zu deren anwendung
SE9604581D0 (sv) An agent against cancer and virus infections
WO2003035889A3 (en) Compositions and methods for bacteria detection
BR9711273A (pt) 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
ATE425758T1 (de) Modifizierte polysaccharide mit veranderter biologischer erkennung
BR0115856B1 (pt) composição betuminosa, e, uso da composição.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties